Chinese patent medicines for coronary microvascular disease: clinical evidence and potential mechanisms

被引：6

作者：

Yang, Zhihua ^{[1
,2
]}

Liu, Yangxi ^{[1
]}

Song, Zhihui ^{[2
]}

Fan, Yujian ^{[1
]}

Lin, Shanshan ^{[1
]}

Ge, Zhao ^{[1
]}

Feng, Shaoling ^{[1
]}

Liu, Yu ^{[1
]}

Bi, Yingfei ^{[1
]}

Wang, Yi ^{[1
]}

Wang, Xianliang ^{[1
]}

Mao, Jingyuan ^{[1
]}

机构：

[1] Tianjin Univ Tradit Chinese Med, Natl Clin Res Ctr Chinese Med Acupuncture & Moxibu, Teaching Hosp 1, Tianjin 300381, Peoples R China

[2] Tianjin Univ Tradit Chinese Med, Inst Tradit Chinese Med, Tianjin 301617, Peoples R China

来源：

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES | 2023年 / 20卷 / 08期

基金：

中国国家自然科学基金;

关键词：

coronary microvascular disease; traditional Chinese medicine; Chinese patent medicines; clinical evidence; potential; Coronary microvascular disease (CMVD) refers; C-REACTIVE PROTEIN; REPERFUSION INJURY; NO-REFLOW; DYSFUNCTION; TONGXINLUO; PATHOPHYSIOLOGY; PHOSPHORYLATION; INFLAMMATION; RESISTANCE; ISCHEMIA;

D O I：

10.7150/ijms.85789

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Coronary microvascular disease (CMVD) is a high risk factor for many cardiovascular events. Due to the limited understanding of its pathophysiological mechanism, modern medicine still lacks therapeutic drugs for CMVD. Existing clinical studies have shown that traditional Chinese medicine (TCM) can effectively improve the clinical symptoms and quality of life of CMVD patients. As an indispensable part of TCM, Chinese patent medicines (CPMs) are widely used in clinical practice. In the face of numerous oral CPMs for treatment of CMVD, how to choose a reasonable medication regimen is one of the important issues in clinic. Based on this, this paper reviewed the clinical efficacy and recommended level of 12 CPMs in the treatment of CMVD, which are recommended by expert consensus on diagnosis and treatment of coronary microvascular disease with integrated Chinese and Western medicine (WM). In addition, this study also systematically summarized the possible mechanisms of CPMs in the treatment of CMVD by protecting coronary microvascular endothelial cells, improving vascular endothelial function, inhibiting inflammation, reducing oxidative stress, promoting angiogenesis, and improving hemorheology, aiming to provide meaningful information for its clinical application.

引用

页码：1024 / 1037

页数：14

共 87 条

[1] Baseline High-Sensitivity C-Reactive Protein Predicts Macrovascular and Microvascular Complications of Type 2 Diabetes: A Population-Based Study [J].

Aryan, Zahra ;

Ghajar, Alireza ;

Faghihi-Kashani, Sara ;

Afarideh, Mohsen ;

Nakhjavani, Manouchehr ;

Esteghamati, Alireza .

ANNALS OF NUTRITION AND METABOLISM, 2018, 72 (04) :287-295

[2]

Bai YH, 2022, CHINESE J DIFFICULT, V21, P119

[3]

[中国老年医学学会心血管病分会 Cardiovascular Disease Branch of Chinese Geriatric Society], 2020, [中国循环杂志, Chinese Circulation Journal], V35, P1149

[4] Association of depression and obesity with C-reactive protein in Germany: A large nationally representative study [J].

Chae, Woo Ri ;

Nuebel, Julia ;

Baumert, Jens ;

Gold, Stefan M. ;

Otte, Christian .

BRAIN BEHAVIOR AND IMMUNITY, 2022, 103 :223-231

[5]

Chang CL, 2019, DRUG EVALUATION RES, V42, P917

[6]

Chen B., 2018, J Integr Cardiovasc Cerebrovasc Dis Chin West Med, V16, P2116, DOI DOI 10.12102/J.ISSN.1672-1349.2018.15.002

[7]

Chen B.Z., 2022, CHINESE J INTEGRATIV, V20, P182, DOI 10.12102/j.issn.1672-1349.2022.01.041

[8]

[陈丰 Chen Feng], 2011, [中成药, Chinese Traditional Patent Medicine], V33, P2041

[9]

Chen R., 2012, Chinese Community Doctors, V28, P15

[10] Tongmai Yangxin pill reduces myocardial no-reflow by regulating apoptosis and activating PI3K/Akt/eNOS pathway [J].

Chen, Rui ;

Chen, Ting ;

Wang, Tianqi ;

Dai, Xiangdong ;

Meng, Ke ;

Zhang, Shuying ;

Jiang, Di ;

Wang, Yanyan ;

Zhou, Kun ;

Geng, Tong ;

Xu, Jinpeng ;

Wang, Yi .

JOURNAL OF ETHNOPHARMACOLOGY, 2020, 261

← 1 2 3 4 5 6 7 8 9 →